Article Sidebar

Submitted
Dec 5, 2025
Accepted
Jan 9, 2026
Published
Jan 18, 2026
Download
pdf
Statistic
Read Counter : 16 Download : 8

Downloads

Download data is not yet available.

Main Article Content

Abstract

Ideally, metabolic homeostasis is maintained through stable glucose regulation, balanced lipid metabolism, and effective uric acid clearance under conditions of minimal systemic inflammation. In real clinical conditions, aging and persistent low-grade inflammation frequently disrupt this balance, leading to hyperglycemia, dyslipidemia, and elevated uric acid levels. Current pharmacological management mainly emphasizes metabolic control and may not sufficiently address underlying tissue dysfunction or inflammatory processes. Platelet-rich plasma (PRP) is a blood-derived bioregenerative product containing growth factors with anti-inflammatory and regenerative properties, offering a potential supportive approach for metabolic regulation. Nevertheless, PRP administration has predominantly relied on invasive delivery methods. Nebulization provides a non-invasive pulmonary route that enables rapid systemic absorption, representing an alternative delivery strategy. Despite its potential advantages, clinical evidence regarding the metabolic effects of PRP delivered via nebulization remains limited, creating an urgent need for preliminary clinical evaluation. Therefore, this pre–post test study aimed to assess the effects of allogeneic PRP nebulization on random blood glucose, uric acid, and total cholesterol levels. Fourteen adult subjects received PRP nebulization for five consecutive days. The intervention resulted in a significant reduction in random blood glucose levels and mild decreasing trends in uric acid and total cholesterol without serious adverse events.

Keywords

Allogeneic Platelet-Rich Plasma Nebulization Blood Suger Level Uric Acid Cholesterol

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
1.
Diah Hastuti, Awal Prasetyo, Anzhari DH, Resti Ariani, Mutia Syafira, Anna Kartika Yuli Astuti, et al. Platelet-Rich Plasma (PRP) Allogenic: A Potential Challenge for Decreasing Random Blood Glucose, Uric Acid, and Cholesterol Levels in A Preliminary Pre and Post Test Study on Adult Subjects. EKSAKTA [Internet]. 2026 Jan. 18 [cited 2026 Jan. 29];27(01):45-5. Available from: https://eksakta.ppj.unp.ac.id/index.php/eksakta/article/view/643

References

  1. [1] Ribeiro, A. K. P. D. L., Carvalho, J. P. R., & Bento-Torres, N. V. O. (2023). Physical exercise as treatment for adults with type 2 diabetes: a rapid review. Frontiers in Endocrinology, 14, 1233906.
  2. [2] World Health Organization, Global Report on Diabetes. Switzerland: Geneva, 2023.
  3. [3] Zheng, L., Zeng, A., Liu, L., Tian, W., Wang, R., Zhang, L., ... & Zhao, J. (2025). Metabolic syndrome: molecular mechanisms and therapeutic interventions. Molecular Biomedicine, 6(1), 59.
  4. [4] Furman, D., Campisi, J., Verdin, E., Carrera-Bastos, P., Targ, S., Franceschi, C., ... & Slavich, G. M. (2019). Chronic inflammation in the etiology of disease across the life span. Nature medicine, 25(12), 1822-1832.
  5. [5] Libby, P., Ridker, P. M., & Maseri, A. (2002). Inflammation and atherosclerosis. Circulation, 105(9), 1135-1143.
  6. [6] Knežević, S., Filippi-Arriaga, F., Belančić, A., Božina, T., Mršić-Pelčić, J., & Vitezić, D. (2024). Metabolic syndrome drug therapy: the potential interplay of pharmacogenetics and pharmacokinetic interactions in clinical practice: a narrative review. Diabetology, 5(4), 406-429.
  7. [7] Pineda-Cortel, M. R., Suarez, C., Cabrera, J. T., Daya, M., Bonifacio, R. B. L., Vergara, R. C., ... & Villavieja, A. (2024). Complexity of Platelet-Rich Plasma: Mechanism of Action, Growth Factor Utilization and Variation in Preparation. Plasmatology, 18, 26348535241277625.
  8. [8] Arif, A., Shakir, M., Shahzad, A., Kawish, N., Sheikh, N., Abbasi, M. H., & Khawar, M. B. (2024). Platelet rich plasma driven changes in hepatic glycogen metabolism and hepato-histological assessment in diabetic mice. Biomedical Research and Therapy, 11(11), 6932-6940.
  9. [9] Zarin, M., Karbalaei, N., Keshtgar, S., & Nemati, M. (2019). Platelet-rich plasma improves impaired glucose hemostasis, disrupted insulin secretion, and pancreatic oxidative stress in streptozotocin-induced diabetic rat. Growth Factors, 37(5-6), 226-237.
  10. [10] El-Tahawy, N. F., Rifaai, R. A., Saber, E. A., Saied, S. R., & Ibrahim, R. A. (2017). Effect of platelet rich plasma (PRP) injection on the endocrine pancreas of the experimentally induced diabetes in male albino rats: a histological and immunohistochemical study. J Diabetes Metab, 8(730), 2.
  11. [11] Everts, P., Onishi, K., Jayaram, P., Lana, J. F., & Mautner, K. (2020). Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. International journal of molecular sciences, 21(20), 7794.
  12. [12] El-Tahawy, N. F., Rifaai, R. A., Saber, E. A., Saied, S. R., & Ibrahim, R. A. (2017). Effect of platelet rich plasma (PRP) injection on the endocrine pancreas of the experimentally induced diabetes in male albino rats: a histological and immunohistochemical study. J Diabetes Metab, 8(730), 2.
  13. [13] Arif, A., Shakir, M., Shahzad, A., Kawish, N., Sheikh, N., Abbasi, M. H., & Khawar, M. B. (2024). Platelet rich plasma driven changes in hepatic glycogen metabolism and hepato-histological assessment in diabetic mice. Biomedical Research and Therapy, 11(11), 6932-6940.
  14. [14] Andia, I., Rubio-Azpeitia, E., & Maffulli, N. (2014). Hyperuricemic PRP in tendon cells. BioMed research international, 2014(1), 926481.
  15. [15] Rieuwpassa, I. E., Minhajat, R., Tetelepta, F. E. N., & Achmad, H. (2019). Effect of Hypercholesterolemia in Platelet Rich Plasma (PRP). Journal of International Dental and Medical Research, 12(3), 980-984.
  16. [16] Izzo, P., De Intinis, C., Molle, M., Polistena, A., Sibio, S., Codacci-Pisanelli, M., ... & Izzo, S. (2023). Case report: The use of PRP in the treatment of diabetic foot: case series and a review of the literature. Frontiers in Endocrinology, 14, 1286907.
  17. [17] Salama, S. M., Kamel, I. H., Ghanim, M., & Elsherif, A. F. (2019). The efficacy of autologous nebulized platelet rich plasma (PRP) as an early adjuvant therapeutic and prognostic treatment modality in the management of inhalation lung injury. The Egyptian Journal of Plastic and Reconstructive Surgery, 43(2), 203-208.
  18. [18] Zhang, Z., Liu, P., Xue, X., Zhang, Z., Wang, L., Jiang, Y., ... & Wang, F. (2025). The role of platelet-rich plasma in biomedicine: A comprehensive overview. IScience, 28(2).
  19. [19] Carvalho, T. C., Peters, J. I., & Williams III, R. O. (2011). Influence of particle size on regional lung deposition–what evidence is there?. International journal of pharmaceutics, 406(1-2), 1-10.
  20. [20] Patton, J. S., & Byron, P. R. (2007). Inhaling medicines: delivering drugs to the body through the lungs. Nature reviews Drug discovery, 6(1), 67-74.
  21. [21] OuYang, H., Tang, Y., Yang, F., Ren, X., Yang, J., Cao, H., & Yin, Y. (2023). Platelet-rich plasma for the treatment of diabetic foot ulcer: a systematic review. Frontiers in Endocrinology, 14, 1256081.
  22. [22] Zarin, M., Karbalaei, N., Keshtgar, S., & Nemati, M. (2019). Platelet-rich plasma improves impaired glucose hemostasis, disrupted insulin secretion, and pancreatic oxidative stress in streptozotocin-induced diabetic rat. Growth Factors, 37(5-6), 226-237.
  23. [23] He, M., Chen, T., Lv, Y., Song, P., Deng, B., Guo, X., ... & Deng, W. (2022). The role of allogeneic platelet-rich plasma in patients with diabetic foot ulcer: Current perspectives and future challenges. Frontiers in Bioengineering and Biotechnology, 10, 993436.
  24. [24] Riskayanti, N. P., Radithia, D., Maharani, A., Hendarti, H. T., Rahayu, R. P., Surboyo, M. D. C., & Ernawati, D. S. (2025). Effect of freeze-dried platelet-rich plasma on FGF-2 and type I collagen expression in traumatic ulcers of diabetes mellitus: An in vivo study. Majalah Kedokteran Gigi, 58(4), 361-366.
  25. [25] Akgul, A., Tarakci, E., Arman, N., Civi, T., & Irmak, S. (2020). A randomized controlled trial comparing platelet-rich plasma, low-level laser therapy, and complex decongestive physiotherapy in patients with lower limb lymphedema. Lymphatic research and biology, 18(5), 439-447.
  26. [26] Almutairi, A. N., & Alazzeh, M. S. (2024). Efficacy and Safety of Platelet-Rich Plasma (PRP) Intra-articular Injections in Hip Osteoarthritis: A Systematic Review of Randomized Clinical Trials. Cureus, 16(10).
  27. [27] Todorov, P., & Batalov, A. (2023). A Gout Flare Caused by the Administration of Platelet Rich Plasma: A Clinical Case.
  28. [28] Tsai, J. (2017). Flare of gout from injection of platelet-rich plasma. Acad Orthop Res Rheum, 1, 106.
  29. [29] Andia, I., Rubio-Azpeitia, E., & Maffulli, N. (2014). Hyperuricemic PRP in tendon cells. BioMed research international, 2014(1), 926481.
  30. [30] Todorov, P., & Batalov, A. (2023). A Gout Flare Caused by the Administration of Platelet Rich Plasma: A Clinical Case.
  31. [31] Dalbeth, N., Gosling, A. L., Gaffo, A., & Abhishek, A. Gout Lancet. 2021; 397: 1843–1855. DOI, 10, S0140-6736.
  32. [32] van der Bijl, I., Vlig, M., Middelkoop, E., & de Korte, D. (2019). Allogeneic platelet‐rich plasma (PRP) is superior to platelets or plasma alone in stimulating fibroblast proliferation and migration, angiogenesis, and chemotaxis as relevant processes for wound healing. Transfusion, 59(11), 3492-3500.
  33. [33] Rachmawati, T., & Wahyuningsih, S. P. A. (2015). The effect of allogenic freeze dried platelet-rich plasma in immunological responses of rabbits. Scholars Academic Journal of Biosciences, 3(4), 325-327.